Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$152.55 USD

152.55
15,971,296

+3.56 (2.39%)

Updated Aug 21, 2026 04:01 PM ET

After-Market: $153.51 +0.96 (0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (161 out of 247)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tracey Ryniec headshot

5 Large Cap Drug Stocks: Values or Traps?

by Tracey Ryniec

Some drug stocks are cheap but is it another fake out?

Kanishka Das headshot

MRK Stock Up Nearly 14% So Far This Week: What's Driving It?

by Kanishka Das

Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.

Ahan Chakraborty headshot

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?

by Ahan Chakraborty

NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.

Sundeep Ganoria headshot

Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?

by Sundeep Ganoria

Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.

Zacks Equity Research

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kanishka Das headshot

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

by Kanishka Das

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

Zacks Equity Research

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

by Zacks Equity Research

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

Zacks Equity Research

Merck (MRK) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $78.56, denoting a +1.24% move from the preceding trading day.

Ekta Bagri headshot

MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?

by Ekta Bagri

Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.